Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ildiko Katay"'
Autor:
Dirk Behringer, Martina Eichstaedt, Jürgen Wolf, Matthias Scheffler, Ahmed Abbas Suleiman, Ildiko Katay, Christian Mattonet, Karin Toepelt, Lukas C. Heukamp, Britta Kaminsky, Fritz Soergel, Dirk Tummes, Sebastian Frechen, Lucia Nogova, Reinhard Buettner, Marc Bos, Roland Schnell, Masyar Gardizi, Thomas Geist, Uwe Fuhr
Publikováno v:
Journal of Clinical Oncology. 31:8112-8112
8112 Background: Dual inhibition of signaling pathways interfering with cell proliferation and angiogenesis may increase anti-tumor efficacy. Sorafenib and mTOR inhibitors showed preliminary activity in KRAS mutated NSCLC. Methods: In the dose escala
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91bd27ab37c81d4bb3f0a16e6ebb2bc7
https://doi.org/10.1200/jco.2013.31.15_suppl.8112
https://doi.org/10.1200/jco.2013.31.15_suppl.8112
Autor:
Markus Dietlein, Ildiko Katay, Marc Bos, Noemi Muthen, Uwe Fuhr, Peter Mallmann, Matthias Scheffler, Max Schlaak, Fritz Soergel, Irini Papachristou, Roland Schnell, Deniz Kahraman, Juergen Wolf, Christian Mattonet, Masyar Gardizi, Lucia Nogova, Martina Kinzig, Carsten Kobe, Kerstin Rhiem, Denis Rokitta
Publikováno v:
Journal of Clinical Oncology. 30:3044-3044
3044 Background: Dual inhibition of signaling pathways interfering with angiogenesis and cell proliferation may increase anti-tumor efficacy. We evaluated the combination of the VEGFR inhibitor sorafenib (S) and the mTOR inhibitor everolimus (E) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1180460364e27d930ecef9ecbff74b8
https://doi.org/10.1200/jco.2012.30.15_suppl.3044
https://doi.org/10.1200/jco.2012.30.15_suppl.3044
Autor:
Christian Mattonet, H. Backes, Karin Toepelt, Thomas Elter, Matthias Scheffler, Carsten Kobe, Lucia Nogova, U. T. Hacker, Ildiko Katay, Nadia Harbeck, Peter Mallmann, Markus Dietlein, N. Muthen, Uwe Fuhr, Irini Papachristou, Kerstin Rhiem, Martin L. Sos, Roland Schnell, Juergen Wolf, M. Reiser
Publikováno v:
Journal of Clinical Oncology. 29:e13613-e13613
e13613 Background: The combination of the multi-kinase inhibitor sorafenib (S) and the mTOR inhibitor everolimus (E) may increase anti-tumor efficacy by dual inhibition of key nodules of signaling ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55a2089a97ae296a7e29db685379581e
https://doi.org/10.1200/jco.2011.29.15_suppl.e13613
https://doi.org/10.1200/jco.2011.29.15_suppl.e13613
Autor:
Christian Mattonet, Irini Papachristou, Juergen Wolf, Matthias Scheffler, Ildiko Katay, Lucia Nogova, Peter Mallmann, Uwe Fuhr, Markus Dietlein, R. Krais
Publikováno v:
Journal of Clinical Oncology. 28:TPS170-TPS170
TPS170 Background: Clinical efficacy of the multikinase inhibitor sorafenib is mainly based on its antiangiogenic properties mediated by VEGFR inhibition. The mTOR inhibitor everolimus also exerts ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e2800fb44745a881fa71b45e61f0e19
https://doi.org/10.1200/jco.2010.28.15_suppl.tps170
https://doi.org/10.1200/jco.2010.28.15_suppl.tps170